Edition:
United Kingdom

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

6.19USD
3:31pm GMT
Change (% chg)

$0.01 (+0.16%)
Prev Close
$6.18
Open
$6.21
Day's High
$6.22
Day's Low
$6.15
Volume
19,226
Avg. Vol
100,806
52-wk High
$7.24
52-wk Low
$2.26

Latest Key Developments (Source: Significant Developments)

Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Q3 loss per share $0.07 from continuing operations
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article

Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Chromadex Corp :Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing.  Full Article

Chromadex appoints Kevin Farr as new CFO
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Chromadex Corp :Chromadex appoints Kevin Farr as new CFO.Chromadex Corp says ‍Chromadex expects that Thomas Varvaro will transition from Chromadex over coming months to pursue other opportunities​.  Full Article

Chromadex Q4 loss per share $0.06
Thursday, 16 Mar 2017 

Chromadex Corp : Chromadex reports 2016 record revenue as ingredient sales grew 34% . Q4 loss per share $0.06 .Q4 sales rose 29 percent to $5.6 million.  Full Article

Chromadex sees Q4 revenue of about $5.6 mln
Tuesday, 14 Feb 2017 

Chromadex Corp : Chromadex expects to report record fourth quarter as revenue increased approximately 29% . Sees Q4 2016 revenue about $5.6 million .Sees FY 2016 revenue about $26.8 million.  Full Article

Chromadex- FDA issues GRAS no objection letter to Niagen
Monday, 15 Aug 2016 

Chromadex Corp : GRAS status compliments new dietary ingredient status already received for Niagen . U.S. FDA issues GRAS no objection letter for Niagen .FDA has issued a generally recognized as safe no objection letter, in response to Niagen Nicotinamide Riboside Chloride (NR) GRAS filing.  Full Article

Chromadex reports Q2 earnings per share $0.00
Thursday, 11 Aug 2016 

Chromadex Corp : Chromadex reports record revenue as ingredients sales climb 83 pct compared to previous year period . Q2 earnings per share $0.00 .Q2 sales rose 45 percent to $8.8 million.  Full Article

Chromadex announces $5.25 million registered direct offering
Monday, 6 Jun 2016 

Chromadex Corp : Company agreed to sell 1.1 million shares of its common stock at a per share price of $4.70 . Chromadex announces $5.25 million registered direct offering .Proceeds from transaction will be used to pay off company's existing debt facility.  Full Article

BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore

* CHROMADEX AND WATSONS EXPAND PARTNERSHIP WITH TRU NIAGEN™ RETAIL LAUNCH IN SINGAPORE Source text for Eikon: Further company coverage: